Authors
Latest:
Sequencing Osimertinib in Patients With EGFR-Mutated NSCLCAparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.
Latest:
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular CarcinomaMahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Latest:
Glofitamab Leads to Responses in Relapsed/Refractory LBCLCyrus M. Khan, MD, discusses the eligibility criteria of a phase 1/2 study evaluating glofitamab for the treatment of patients with large B-cell lymphoma, and provides data from the expansion cohorts of the trial.
Latest:
Early Trial Targeting CLL1-Positive Cells Demonstrates Efficacy in Pediatric AMLA small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia showed efficacy and safety with anti-C-type lectin-like molecule-based chimeric antigen receptor T cells.
Latest:
Post–COVID-19 Infection Remains a Concern in Patients With CancerMany questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Latest:
Treating Patients With Prostate Cancer During COVID-19 Era Poses New ChallengesMonica L. Baskin, PhD, addresses the biggest challenges in treating patients with prostate cancer during the COVID-19 era.
Latest:
Emerging Treatments in Ovarian Cancer and Advice for Community OncologistsDr Chirag A. Shah highlights novel emerging treatments in ovarian cancer and provides advice for community oncologists.
Latest:
Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric CancerYu Sunakawa, MD, PhD, discusses the data observed in the DELIVER trial, which was presented as an updated analysis of nivolumab in patients with advanced gastric cancer at the European Society of Oncology World Congress on Gastrointestinal Cancer 2020.
Latest:
Clinical Pearls and Future Directions of Cervical Cancer TreatmentRitu Salani, MD, offers advice for community oncologists treating patients with cervical cancer and discusses the future directions of the treatment landscape.
Latest:
Advancements Needed in the Esophageal Cancer SpaceAllan Pickens, MD, discusses the current treatment landscape for esophageal cancer.
Latest:
Background of De-Escalation Approach to HER2+ Breast Cancer TreatmentNeil Vasan, MD, PhD, discusses how past studies have supported de-escalated approaches and other improvements to treatment for patients with HER2-positive breast cancer.
Latest:
Lutetium-PSMA-617 and Novel Agents in Prostate CancerOncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.
Latest:
Phase 1/2 Study Tests Quizartinib/Venetoclax/Decitabine in FLT3-ITD AMLMusa Yilmaz, MD, discusses the most recent update of the phase 1/2 study of quizartinib, venetoclax, and decitabine in FLT3-internal tandem duplication mutated acute myeloid leukemia and the background behind this research.
Latest:
In Endometrial Cancer Treatment, Racial Disparities PersistAn increased risk of death and lower enrollment in clinical trials have been observed between Black and White patients with endometrial cancer.
Latest:
Future Directions for the CLL SpaceCarolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.
Latest:
Medical Spending in Community PracticesJosh Weitz, MD, discusses how to balance cost-savings and efficiency while maximizing patient satisfaction in his medical practice.
Latest:
EP. 8B: Reactive and Proactive Treatment Approaches for the Management of Chemotherapy-Induced MyelosuppressionIn this companion article, Dr. Estelamari Rodriguez reflects on the role of reactive and proactive treatment approaches for the management of chemotherapy-induced myelosuppression in small cell lung cancer.
Latest:
Excitement Around Cilta-Cel in Multiple MyelomaYi Lin MD, PhD, discusses the impact of the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of relapsed or refractory multiple myeloma.
Latest:
BPDCN: Future Directions in CareClosing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.
Latest:
TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell CarcinomaSumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.
Latest:
Predicting the Clinical Trials of the Future: Top 4 Trends to WatchLaura Fernandes, PhD, Senior Statistical Director of COTA, Inc, gives 4 predictions of upcoming trends that will change how clinical trials are performed.
Latest:
Frontline Treatment Options for Patients With BPDCNExplores the intricate decision-making process for frontline treatment in BPDCN patients, with considerations for age, fitness, and various therapeutic approaches.
Latest:
Closing Thoughts on Recent Data in GI Cancers From ESMO 2023Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.
Latest:
Lung Cancer Awareness Month: New Targeted Therapy Options in Advanced NSCLCSurabhi Pathak, MD, reviews current and upcoming targeted treatments in patients with non–small cell lung cancer for Lung Cancer Awareness Month.
Latest:
Differences in Toxicity Based on Race in Nonsquamous NSCLCNino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.
Latest:
Ontada's EHR Tools Power Real-World Research Solutions in the Community Oncology SettingIn an interview with Targeted Oncology, Robert Reid, MD, discussed how the utilization of Ontada’s solutions helps to improve community-based research across the field of oncology.
Latest:
New Liquid Biopsy Method May Improve Upon Current Modalities for Early Detection of CancerVictor Velculescu, MD, PhD, discusses the key takeaways regarding the use of liquid biopsy to detect cancer and a new cfDNA approach to detect cancer at earlier stages.
Latest:
Sabatolimab Appears Promising for Combination Use With HMAs in AML, MDSAndrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
Latest:
Continued Role for Transplantation in NDMMBefore closing out his discussion on newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, emphasizes the continued role of transplantation in this setting.
